First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer (DBCOND0157242)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05838066	Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.	Anbenitamab Docetaxel Pertuzumab Trastuzumab	treatment	3	not_yet_recruiting